Skip to main content

Table 2 Patient characteristics

From: Achievement of renal anemia KDIGO targets by two different clinical strategies – a European hemodialysis multicenter analysis

  All Portugal Poland p*
(%) (%) (%)
Hemoglobin 10–12 g/dL 67.3 65.8 69.5 N.S.
Hemoglobin > 12 g/dL 15.2 15.3 15.1 N.S.
Ferritin ≥200 μg/L 84.4 82.9 86.6 N.S.
Ferritin ≥800 μg/L 24.0 15.8 35.6 <  0.001
TSAT ≥20% 81.5 76.3 88.8 <  0.001
TSAT ≥50% 9.4 5.7 14.6 <  0.001
Treatment with ESA 76 78 74 0.056
Type of ESA N.S.
 Darbepoietin 24 22 26
 Epoetin beta 76 78 74
Route of ESA administration <  0.001
 Intravenous 64.5 99.8 11.5
 Subcutaneous 35.5 0.2 88.5
ESA administration, frequency <  0.001
 No ESA 23.6 21.7 26.3
 Every other week 0.4 0.7 0
 Once per week 15.0 2.1 33.2
 Twice per week 15.9 11.1 22.6
 Three times per week 45.1 64.5 18.0
Dialysis modality <  0.001
 HDF 46.6 91.4 0
 HD 53.4 8.6 100
spKt/V > 1.2 97.3 98.5 95.6 0.003
URR ≥ 70% 90.8 95.4 84.4 <  0.001
Treatment time ≥ 12 h/week 93.8 94.0 93.6 N.S.
Prescribed Qb ≥ 300 mL/min 94.1 97.4 89.4 <  0.001
Treated blood volume ≥ 1 L/kg body weight 90.0 95.7 81.9 < 0.001
CVC (%) 16.5 14.5 19.3 0.026
AV Fistula (%) 76.8 77.1 76.4 N.S.
S-Albumin ≥35 g/L 89.7 95.4 81.8 < 0.001
Charlson comorbidity index < 0.001
  < 7 44.5 39.1 52.1
 7–12 51.9 56.7 45.2
  > 12 3.6 4.3 2.7
Diabetes mellitus 26 30 25 N.S.
Phosphorus ≤5.5 mg/dL 82.0 87.5 74.2 < 0.001
Calcium ≤10.2 mg/dL 98.1 98.0 98.2 N.S.
PTH 150–600 pg/mL 53.9 52.1 56.4 N.S.
  1. * Chi-2 analysis between countries